These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18706377)

  • 1. [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
    Ferrière JM; Wallerand H; Bernhard JC; Cornu JN; Rouprêt M; Ravaud A
    Prog Urol; 2008 Jul; 18 Suppl 4():S88-91. PubMed ID: 18706377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management].
    Audenet F; Rouprêt M; Méjean A
    Prog Urol; 2009 Oct; 19(9):596-605. PubMed ID: 19800548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
    Leroy X; Edeline J; Rioux-Leclercq N
    Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy?
    Soulières D
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):153-6. PubMed ID: 19512932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives.
    Timsit MO; Albiges L; Méjean A; Escudier B
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1559-69. PubMed ID: 23253222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metastatic renal cell carcinoma: pretherapeutic approach before antiangiogenic treatment. A case report].
    Méjean A; Guy L; Jacqmin D; Joly F; Négrier S; Pignot G
    Prog Urol; 2010 Mar; 20 Suppl 1():S16-9. PubMed ID: 20493437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.
    Wood CG; Margulis V
    Cancer; 2009 May; 115(10 Suppl):2355-60. PubMed ID: 19402066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives].
    Oudard S; Cornu JN; Rouprêt M; Patard JJ
    Prog Urol; 2008 Jul; 18 Suppl 4():S77-80. PubMed ID: 18706375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
    Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
    Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination therapy of localized and locally-advanced renal-cell cancer using preoperative arterial embolization].
    Karelin MI; Atroshchenko AV; Shkol'nik MI; Leonenkov RV; Belov AD; Kharitonov MV
    Vopr Onkol; 2008; 54(1):95-7. PubMed ID: 18416067
    [No Abstract]   [Full Text] [Related]  

  • 11. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
    Wood CG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
    de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
    Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New treatment of metastatic renal cancer. The Danish Society of Clinical Oncology].
    Sengeløv L; Geertsen PF;
    Ugeskr Laeger; 2007 Mar; 169(12):1117. PubMed ID: 17394828
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.
    Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG
    J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant and adjuvant treatment of renal cell carcinoma.
    Thillai K; Allan S; Powles T; Rudman S; Chowdhury S
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):765-76. PubMed ID: 22716493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy.
    Di Silverio F; Sciarra A; Parente U; Andrea A; Von Heland M; Panebianco V; Passariello R
    Urol Int; 2008; 80(4):451-3. PubMed ID: 18587261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutics for metastatic renal cell carcinoma.
    Hutson TE; Figlin RA
    Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.
    Ebbinghaus S; Hussain M; Tannir N; Gordon M; Desai AA; Knight RA; Humerickhouse RA; Qian J; Gordon GB; Figlin R
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6689-95. PubMed ID: 18006769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metastatic kidney cancer: new therapeutic approaches].
    Negrier S; Mejean A; Oudard S; Escudier B
    Prog Urol; 2002 Sep; 12(4):703-8. PubMed ID: 12463140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.